Compare Monster Beverage Corp (MNST) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Neurocrine Biosciences Inc — how do they compare? Monster Beverage Corp trades at $42.97 (market cap $84.53B), while Neurocrine Biosciences Inc trades at $155 (market cap $15.77B). The key difference: Monster Beverage Corp is far larger — about 5.4× Neurocrine Biosciences Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| MNST | NBIX | |
|---|---|---|
Market Cap | $84.53B | $15.77B |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $185.50 |
52-Week Low | $31.41 | $123.10 |
Enterprise Value | $82.83B | $15.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.15, down 1.53% on the day, following a recent 2-for-1 stock split completed August 11, 2026. The stock shows strong fundamental performance with revenue growing from $6.3B in 2022 to $8.3B in 2025, while net income expanded to $1.91B. Technical indicators present a mixed picture with bullish oscillators but bearish moving averages, creating uncertainty in the near-term direction. Analyst consensus remains positive with 51% buy ratings and a $51.10 price target representing 18% upside potential.
MNST offers compelling growth prospects driven by 20%+ revenue growth and expanding international presence (46% of Q2 2026 sales). However, elevated valuation multiples (P/E 39.95, P/S 9.24) and rising cost pressures present risks. The company's consistent earnings beats and strong cash flow generation support the bullish case, but investors should weigh growth potential against premium valuation in a competitive beverage market.
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
